Dry eye disease (DED) remains a leading cause of ocular discomfort and decline in vision-related quality of life, particularly among women aged 30 years and older. This demographic is disproportionately affected due to a confluence of hormonal, occupational, and behavioral risk factors. Among these, digital device usage has emerged as a significant contributor to ocular surface compromise, inducing both evaporative and aqueous-deficient dry eye. With the shift toward virtual environments and prolonged screen exposure, clinicians must adapt treatment protocols to address the unique needs of this growing patient segment. One of the most underutilized but clinically effective strategies is the use of nighttime ocular ointments.

Pathophysiology of Dry Eye in Women Aged 30+

Women over 30 often experience subtle hormonal fluctuations, particularly in estrogen and androgen levels, which can impact lacrimal gland function and meibomian gland activity. Estrogen modulates inflammatory pathways and tear film stability, while androgens maintain meibomian gland lipid production. As these hormones decline, the ocular surface becomes more susceptible to instability and inflammation, creating a physiologic environment conducive to DED.

Additionally, this population frequently engages in occupations or lifestyles requiring extended digital screen use. Numerous studies have confirmed that screen time reduces spontaneous blink rates by up to 60%, resulting in incomplete blinking and inadequate meibomian gland expression. The consequence is a compromised tear film lipid layer, accelerated tear evaporation, and increased ocular surface exposure.

Impact of Digital Eye Strain on Tear Film Integrity

Digital eye strain (DES), also known as computer vision syndrome, is now recognized as a significant contributor to dry eye symptoms in women within the 30–55 age range. The mechanism is multifactorial:

• Decreased Blink Rate: Studies demonstrate a drop from 15–20 blinks per minute to fewer than 5 during prolonged screen use.

• Incomplete Blinking: Inhibits full meibum release, contributing to lipid layer deficiency.

• Ocular Surface Inflammation: Chronic exposure to dry air from indoor environments and blue light may exacerbate inflammation, further destabilizing the tear film.

The resulting condition is often subclinical evaporative dry eye that progresses to symptomatic disease, particularly in perimenopausal women who experience compounded hormonal changes.

Role of Nighttime Ointments in Dry Eye Management

Nighttime ointments serve as an effective adjunctive or primary therapy for moderate to severe DED, especially in patients whose symptoms worsen at night or upon waking.

Mechanism of Action

Ocular ointments typically consist of petrolatum- or lanolin-based formulations that provide prolonged ocular surface residence during the hours of sleep. Unlike daytime drops, ointments do not rely on blinking to distribute or maintain surface coverage. Instead, they act as a barrier to evaporation and as an occlusive moisturizer, promoting epithelial healing and tear film restoration during the naturally low tear production period of sleep.

Benefits of Nighttime Application

• Enhanced Contact Time: Ointments remain on the ocular surface for 6–8 hours, surpassing the retention time of artificial tears.

• No Interference with Daily Vision: The blurring effect of ointments is mitigated by nighttime use.

• Facilitates Glandular Recovery: Nighttime thermal therapies or ointment combinations may support meibomian gland patency and lipid regeneration.

• Symptom Relief Upon Waking: Many patients report significant improvement in morning dryness and irritation.

Clinical Relevance of EYELIVIO for Women with Digital Eye Strain

EYELIVIO is a dual-component nighttime therapy consisting of a self-heating eye mask and a lipid-based topical ointment designed for nightly use. The heat component facilitates meibomian gland expression, while the ointment provides prolonged lubrication and epithelial protection during sleep.

Unique Advantages

• Targeted for Evaporative Dry Eye: Especially effective in DES patients with lipid layer deficiency.

• Improves Morning Comfort: Patients report decreased lid stickiness, reduced foreign body sensation, and better morning vision quality.

• Supports Compliance: Once-daily, nighttime application enhances adherence compared to frequent daytime drop regimens.

In clinical observations, patients using EYELIVIO nightly for two weeks showed a marked reduction in symptom severity scores (OSDI), improved non-invasive tear break-up time (NIBUT), and enhanced meibomian gland secretion quality. These effects are particularly beneficial for digitally active women whose meibomian dysfunction is exacerbated by environmental and behavioral factors.

Incorporating EYELIVIO into your nightly routine can provide lasting relief, particularly for women whose daytime screen use contributes to persistent dry eye symptoms.

Clinical Recommendations for Eye Care Practitioners

For women aged 30 and older presenting with signs of digital eye strain and dry eye:

• Assess Blink Patterns and Gland Function: Use meibography or tear film interferometry if available.

• Educate on Lifestyle Modifications: Encourage regular blinking, screen breaks, and humidified environments.

• Initiate Nighttime Ointment Therapy: Particularly for patients with significant morning symptoms or low nighttime tear secretion.

• Recommend EYELIVIO in Moderate-to-Severe Cases: Especially when MGD or lipid tear deficiency is evident.

This approach not only addresses the root physiological issues but also offers a practical, patient-friendly strategy with minimal systemic risk.

Conclusion

Women over the age of 30 face a distinct combination of hormonal and environmental challenges that predispose them to dry eye disease. With digital device usage continuing to rise, effective, low-maintenance treatments are critical. Nighttime ointments offer significant clinical benefit by restoring tear film integrity during sleep. Among these, EYELIVIO provides a comprehensive solution by combining heat and lubrication to counteract evaporative stress. As frontline eye care providers, optometrists and ophthalmologists must consider integrating nighttime therapy into standard dry eye management protocols, especially for digitally active women in this demographic.

References:

1. Schaumberg DA, et al. Prevalence of dry eye disease among US men and women using a large claims database. Am J Ophthalmol. 2013;156(6):1124–1129.e1.
2. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med. 1993;328(8):584.
3. Wu H, et al. Age-related changes in dry eye: A review of clinical and experimental findings. Exp Eye Res. 2020;195:108001.
4. Stapleton F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-365.
5. Craig JP, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283.
6. Aragona P, et al. Ocular surface disease and keratopathy in menopause. J Clin Med. 2020;9(9):2793.
7. Liu H, et al. Changes in blink behavior and ocular surface symptoms during different visual tasks. Invest Ophthalmol Vis Sci. 2013;54(7):4941–4948.
8. Management Report: Internal EYELIVIO Clinical Use Assessment (2024). Data on file.
9. Sullivan DA, et al. Sex, gender, and dry eye: An analysis of the impact of sex and sex hormones on aqueous tear secretion. Ocul Surf. 2020;18(2):321–336.
10. Baudouin C, et al. Preservatives in eyedrops: The good, the bad, and the ugly. Prog Retin Eye Res. 2010;29(4):312–334.